Found 40 clinical trials
The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
- 7 views
- 15 Mar, 2022
- 5 locations
GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a.
- 324 views
- 12 Feb, 2022
- 65 locations
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3009 dose to be tested in a larger group of patients and …
- 17 views
- 25 Mar, 2022
- 14 locations
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)
with High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise Specified.
- 34 views
- 01 Mar, 2022
- 1 location
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Background Burkitt Lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive B cell lymphomas. Frontline treatment does not always work. Researchers want to see if a combination of drugs can help. Objective To learn if it is safe to give people with certain cancers copanlisib together with rituximab and …
- 0 views
- 16 May, 2022
- 1 location
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
- 38 views
- 05 Feb, 2022
- 10 locations
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double or triple hit lymphoma. Polatuzumab vedotin is a monoclonal antibody that works by binding with cancer cells and releasing another chemotherapy drug, called monomethyl auristatin E, into the cell causing …
- 0 views
- 22 Mar, 2022
- 2 locations
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
- 0 views
- 22 Mar, 2022
- 1 location
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)
vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma or High Grade B-Cell Lymphoma.
- 0 views
- 06 May, 2022
- 13 locations
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma
, invasive lymphoma and inert lymphoma; Highly invasive NHL included Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL), high-grade B-cell lymphoma, etc; Invasive NHL includes diffuse large B-cell lymphoma
- 0 views
- 27 Jan, 2021
- 1 location